Keywords: roberts, purchases, rights, agrylin, b-ms, pharmaceutical, purchased
Roberts purchases rights to Agrylin from B-MS
Article | 24 June 1999
Roberts Pharmaceutical has purchased all rights to itsthrombocythemia therapy Agrylin (anagrelide HCl) from Bristol-Myers Squibb. The transaction ends all royalty ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
